Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع ادوية أدونيس - adonis drug store - vancomycin hcl equivalent to 0.5 g vancomycin - equivalent to 0.5 g vancomycin

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع ادوية أدونيس - adonis drug store - vancomycin hcl equivalent to 0.5 g vancomycin - equivalent to 0.5 g vancomycin

Malta - English - Medicines Authority

merz pharmaceuticals gmbh eckenheimer landstrasse 100, d-60318 frankfurt am main, germany - l, ornithine, aspartate - concentrate for solution for infusion - l-ornithine 5 g/ml l-aspartate 5 g/ml - bile and liver therapy

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

laboratoire français du fractionnement et des biotechnologies s.a. - human fibrinogen humain 1,5 g - powder and solvent for solution for injection/infusion - 1,5 g - human fibrinogen 1.5 g - fibrinogen, human

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - piperacillin sodium, quantity: 4.253 g; tazobactam sodium, quantity: 0.547 g (equivalent: tazobactam, qty 0.5 g) - injection, powder for - excipient ingredients: - pipertaz sandoz is used to treat serious bacterial infections caused by susceptible strains of beta-lactamase producing organisms in the conditions listed below: 1) lower respiratory tract infections; 2) urinary tract infections (complicated and uncomplicated); 3) intra-abdominal infections; 4) skin and skin structure infections; 5) bacterial septicaemia; 6) gynaecological infections. children under the age of 12 years: in hospitalised children aged 2 to 12 years, pipertaz sandoz is indicated for the treatment of serious intra-abdominal infections. it has not been evaluated in children below the age of 2 years. while pipertaz sandoz (piperacillin/tazobactam) is indicated only for the conditions listed above, it may be used as a single agent in the treatment of mixed infections caused by piperacillin susceptible and beta-lactamase producing, piperacillin-resistant organisms. appropriate culture and susceptibility tests should be performed before treatment in order to identify organisms causing infection to determine their susceptibility to pipertaz sandoz (piperacillin/tazobactam). therapy with pipertaz sandoz (piperacillin/tazobactam), however, may be initiated before results of each test are known when there is reason to believe the infection may involve any of the beta-lactamase producing organisms listed above, however, once these results are available, appropriate therapy should be continued. in serious infections, presumptive therapy with pipertaz sandoz (piperacillin/tazobactam) may be initiated before susceptibility test results are available. combination therapy with pipertaz sandoz (piperacillin/tazobactam) and aminoglycosides may be used int he treatment of serious infections caused by pseudomonas aeruginosa. both drugs shold be used in full therapeutic doses. as soon as results of culture and susceptibility tests become available, antimicrobial therapy should be adjusted.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - cefuroxime sodium 1.578 g equivalent to 1.5 g cefuroxime;  ;   - powder for injection - 1.5 g - active: cefuroxime sodium 1.578 g equivalent to 1.5 g cefuroxime     - cefuroxime is a bactericidal cephalosporin antibiotic which is resistant to most ?-lactamases and is active against a wide range of gram-positive and gram-negative organisms. it is indicated for the treatment of infections before the infecting organism has been identified or when caused by sensitive bacteria. susceptibility to cefuroxime sodium will vary with geography and time and local susceptibility data should be consulted where available. indications include - respiratory tract infections for example, acute exacerbation of chronic bronchitis, infected bronchiectasis, bacterial pneumonia, lung abscess and post-operative chest infections. - ear, nose and throat infections for example, sinusitis, tonsillitis, pharyngitis and otitis media. - urinary tract infections for example, acute and chronic pyelonephritis, cystitis and asymptomatic bacteriuria. - soft-tissue infections for example, cellulitis, erysipelas and wound infections. - bone and joint infections for example, osteomyelitis and septic ar

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - colestipol hydrochloride 5 g - granules for oral suspension - 5 g - active: colestipol hydrochloride 5 g - colestid is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol and low-density lipoprotein (ldl) cholesterol in patients with primary hypercholesterolaemia (elevated low density lipoproteins (ldl) cholesterol) who do not respond adequately to diet and to reduce the risks of atherosclerotic coronary artery disease and myocardial infarction. it may be used as the sole agent or in combination with additional lipid lowering agents. when compared to conventional measures, intensive lipid-lowering combination therapy, which included colestid plus either niacin or lovastatin, significantly reduced the frequency of progression and increased the frequency of regression of coronary atherosclerotic lesions in patients with, or at risk for, symptomatic coronary artery disease

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - sulfadiazine 0.5 g; sulfadimidine 0.5 g; sulfafurazole 0.5 g - tablet - 0.5 g - active: sulfadiazine 0.5 g sulfadimidine 0.5 g sulfafurazole 0.5 g

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sanofi belgium sa-nv - sorbitol 5 g - powder for oral solution - 5 g - sorbitol 5 g - sorbitol

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sanofi belgium sa-nv - sorbitol 5 g - powder for oral solution - 5 g - sorbitol 5 g - sorbitol